Thierry Façon

Inserm — France

Medicine · Health Sciences

113h-index61.2kcitations953works7.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(790), Protein Degradation and Inhibitors(302), Cancer Treatment and Pharmacology(198), Peptidase Inhibition and Analysis(153), Chronic Lymphocytic Leukemia Research(127)

Publications950 total

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)
Blood·2025
Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients
Blood·2025· 1 citedOpen Access
Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry
Blood·2025Open Access
A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a
Blood·2025Open Access
Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)
Blood·2025Open Access
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Blood Cancer Journal·2025· 1 citedOpen Access
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant
Future Oncology·2025Open Access
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
The Lancet Oncology·2025· 5 citedOpen Access
DARATUMUMAB + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE)/TRANSPLANT-DEFERRED (TD) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS
Hematology Transfusion and Cell Therapy·2025Open Access
DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF TRANSPLANT- INELIGIBLE (TIE) PATIENTS IN THE PHASE 3 CEPHEUS STUDY
Hematology Transfusion and Cell Therapy·2025Open Access
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRANSPLANT-INELIGIBLE OR TRANSPLANT-DEFERRED NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) IN THE PHASE 3 CEPHEUS TRIAL
Hematology Transfusion and Cell Therapy·2025Open Access
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial
Blood·2025· 1 cited
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Blood Advances·2025· 2 citedOpen Access
Isa-VRd Improves Outcomes in High-Risk Newly Diagnosed Transplant-Ineligible Multiple Myeloma Using the IMS/IMWG Consensus HR Definition: Results from the BENEFIT Phase 3 Trial (IFM 2020–05)
Clinical Lymphoma Myeloma & Leukemia·2025
Dynamic Frailty Analysis of Transplant-Ineligible (TIE) Patients with NDMM in the Phase 3 MAIA and CEPHEUS Trials of Daratumumab (Dara) + Lenalidomide-Dexamethasone (Rd) and Bortezomib-Rd (VRd)
Clinical Lymphoma Myeloma & Leukemia·2025
Farorable Outcome of Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy; IFM Experience from the Descar-T Registry
Clinical Lymphoma Myeloma & Leukemia·2025
Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Efficacy of Daratumumab-Bortezomib-Lenalidomide-Dexamethasone (DVRd) vs Daratumumab-Lenalidomide-Dexamethasone (DRd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
Patient-Reported Outcomes (PROs) and Safety in Patients (Pts) With NDMM Achieving MRD Negativity and ≥CR (MRDneg) in the Phase 3 PERSEUS and CEPHEUS Trials
Clinical Lymphoma Myeloma & Leukemia·2025
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022–05)
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 48Next →

Frequent Co-authors

Philippe Moreau(35), Michel Attal(21), Hervé Avet‐Loiseau(19), Meletios Α. Dimopoulos(18), Jean‐Luc Harousseau(16), Xavier Leleu(16), Paul G. Richardson(15), Lotfi Benboubker(13), Pieter Sonneveld(12), Hartmut Goldschmidt(12), Jesús F. San Miguel(12), Michèle Cavo(12), Cyrille Hulin(12), Kenneth C. Anderson(11), Denis Caillot(11), Roman Hájek(10), Laurent Garderet(9), Claire Mathiot(9), Brigitte Pegourié(9), Sagar Lonial(8)